Inactive Instrument

Bioverativ Inc Share Price

Equities

US09075E1001

Biotechnology & Medical Research

Chart Bioverativ Inc

Duration

Period

Style

Latest news about Bioverativ Inc

Sanofi : sees new acquisitions and drugs reviving growth	27/04/18	RE
Takeda Pharmaceutical : Merits of any Takeda bid for Shire questioned, shares slide	29/03/18	RE
Takeda Pharmaceutical : Merits of any Takeda bid for Shire questioned, shares slide	29/03/18	RE
Takeda Pharmaceutical : Drugmaker Shire soars as Japan's Takeda considers bid	28/03/18	RE
Bioverativ : Oxford BioMedica wins second $100 million gene therapy contract	15/02/18	RE
Ablynx : Sanofi's return to profit growth this year slower than hoped	07/02/18	RE
Ablynx : Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom	30/01/18	RE
Stocks hit record as senators reach deal to end shutdown	22/01/18	RE
Compagnie Financiere Richemont : Dealmaking drives European stocks as equity melt-up continues	22/01/18	RE
Ablynx : Biotech M&A takes off as Sanofi and Celgene spend $20 billion	22/01/18	RE
Biogen : Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion	22/01/18	RE
Bioverativ : New drugs recast $10 billion haemophilia market as Sanofi swoops in	22/01/18	RE
Biogen : Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion	22/01/18	RE
Biogen : Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion	22/01/18	RE
Bioverativ : Sanofi shares fall on $11.6 billion Bioverativ takeover	22/01/18	RE

Press releases Bioverativ Inc

Bioverativ : Announces First Patient Dosed in Phase 3 Study of BIVV009 for Treatment of Cold Agglutinin Disease	06/03/18	BU
Bioverativ : Haemophilia Publishes a Retrospective Analysis Investigating the Use of ELOCTATE® for Immune Tolerance Induction in People with Inhibitors and Severe Hemophilia A	14/02/18	BU
Bioverativ : Reports Fourth Quarter and Full Year 2017 Performance	13/02/18	BU
WeissLaw LLP : Investigates Bioverativ Inc. Acquisition	24/01/18	PR
Bragar Eagel & Squire, P.C. : is Investigating the Board of Directors of Bioverativ Inc. (BIVV) on Behalf of Stockholders and Encourages Investors to Contact the Firm	22/01/18	BU

More press releases

News in other languages on Bioverativ Inc

Sanofi : L'offre publique d'achat de Sanofi sur Ablynx débutera le 4 avril	29/03/18
Sanofi finalise l'acquisition de Bioverativ	08/03/18
Bioverativ : Sanofi finalise l'acquisition de Bioverativ, qui quitte la Bourse	08/03/18
Sanofi : franchit une étape dans son offre sur Bioverativ	23/02/18
Sanofi: Amélioration attendue en 2018 plus lente que prévu	07/02/18

Managers and Directors - Bioverativ Inc

Managers	Title	Age	Since
William Sibold PSD	President	-	07/03/18
Joann Nestor SEC	Corporate Secretary	-	-
Timothy J.R. Harris PRN	Corporate Officer/Principal	-	-

Members of the board	Title	Age	Since
William Sibold PSD	President	-	07/03/18
Philippe Sauvage BRD	Director/Board Member	-	07/03/18

Company Profile

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer